A5064626430- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Tea Polyphenols and Effects
- RNA modifications and cancer
- Nanoparticle-Based Drug Delivery
- Prostate Cancer Treatment and Research
- Mechanical and Thermal Properties Analysis
- Extracellular vesicles in disease
- T-cell and B-cell Immunology
- Protein Kinase Regulation and GTPase Signaling
- Lung Cancer Treatments and Mutations
- Engineering Technology and Methodologies
- Metallurgy and Material Forming
- Nanoplatforms for cancer theranostics
- Cancer Mechanisms and Therapy
- Melanoma and MAPK Pathways
- Genetic factors in colorectal cancer
- Food Quality and Safety Studies
Changhai Hospital
2021-2025
Second Military Medical University
2021-2025
Yale University
2023-2025
Yale Cancer Center
2022
Abstract Adoptive transfer of chimeric antigen receptor (CAR)-modified natural killer (NK) cells represents a transformative approach that has significantly advanced clinical outcomes in patients with malignant hematological conditions. However, the efficacy CAR-NK treating solid tumors is limited by their exhaustion, impaired infiltration and poor persistence immunosuppressive tumor microenvironment (TME). As NK cell functional states are associated IL-2 cascade, we engineered...
Despite significant advancements in kinase-targeted therapy, the emergence of acquired drug resistance to targets such as KRAS and MEK remains a challenge. Extracellular-regulated kinase 1/2 (ERK1/2), positioned at terminus this pathway, is highly conserved less susceptible mutations, thereby garnering attention crucial therapeutical target. However, attempts use monotherapies that target ERK1/2 have achieved only limited clinical success, mainly due issues efficacy resistance. Herein, we...
<title>Abstract</title> Despite the proven clinical activity of checkpoint inhibitors (ICIs) in several cancer indications, frequent occurrence primary and secondary resistance reduces their overall effectiveness. Development ICI has been attributed mainly to genetic or epigenic alterations that affect tumor antigen presentation machinery leading diminished anti-tumor immune responses. There is an urgent need for new approaches which can either re-sensitize resistant tumors ICIs engage...
Abstract Purpose: The identification of actionable oncogenic alterations has enabled targeted therapeutic strategies for subsets patients with advanced malignancies, including lung adenocarcinoma (LUAD). We sought to assess the frequency known drivers and identify new candidate in a cohort LUAD from minimal smoking history. Experimental Design: performed genomic characterization 103 LUADs ≤10 pack-year Tumors were subjected molecular profiling and/or whole-exome sequencing RNA search...
Intratumor heterogeneity is a key driver for local relapse and treatment failure. Thus, using multifocal prostate cancer as model to investigate tumor inter-clonal relationships evolution could aid in our understanding of drug resistance. Previous studies discovered genomic alterations by comparing hormone-sensitive (HSPC) with castration-resistant (CRPC) large cohorts. However, most did not sequentially sample tumors from the same patient. In study, we performed whole-exome sequencing (WES)...
Adoptive natural killer (NK) cell transfer has been demonstrated to be a promising immunotherapy approach against malignancies, but requires the administration of sufficient activated cells for treatment effectiveness. However, paucity clinical-grade support large-scale expansion limits its feasibility. Here we developed feeder-based NK that utilizes OX40L armed NK-92 with secreting neoleukin-2/15 (Neo-2/15), hyper-stable mimetic high affinity IL-2Rβγ. The novel feeder (NK92-Neo2/15-OX40L)...
Dampened antigen presentation underscores the resistance of pancreatic cancer to T cell–mediated anti-tumor immunity, rendering immunotherapy largely ineffective. By high-throughput CRISPR activation perturbation, we discovered that transcriptional regulator MCRS1 significantly augmented sensitivity mouse cells cell immunity in vitro and vivo. Mechanistically, interacted with transcription factor genome organizer YY1 coordinately increase chromatin accessibility expression MHC-I genes....
Abstract Exosomes, a specific subset of extracellular vesicles, have diverse functions in various biological processes. In the field cancer research, there has been growing interest potential exosomes to act as versatile vehicles for targeted tumor imaging and therapy. this study, we constructed delivery platform using hypoimmunogenic by genetically modifying β2‐microglobulin knocking‐out HEK‐293F cells express fusion protein, referred αMUC1‐Exo, which comprises exosomal membrane‐enriched...
<h3>Background</h3> Interleukin-12 (IL-12) is a potent activator of anti-tumor immunity, but it's use as systemic therapy limited due to toxicity. MEDI1191 comprises recombinant IL-12 mRNA formulated in lipid nanoparticles for intratumoral (IT) injection resulting high expression the cytokine immediate tumor microenvironment (TME).<sup>1 2</sup> This novel drug tolerated and efficacious preclinical setting.<sup>2</sup> has entered Phase 1 Clinical Development (NCT03439280).<sup>3 4</sup>...